Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium - PubMed
4 hours ago
- #neoadjuvant chemotherapy
- #prognostic factors
- #pancreatic cancer
- Study focuses on restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer (PDAC).
- Aims to assess treatment response, revise prognosis, and guide further management.
- Retrospective international study with 2338 patients categorized by initial staging: 22.6% potentially resectable, 30.7% borderline resectable, 46.7% locally advanced.
- Identified independent prognostic factors for overall survival (OS), including tumor location, performance status, metastatic disease at restaging, CA19-9 levels, and tumor size changes.
- Patients stratified into four risk groups with 3-year OS ranging from 6.0% to 65.8%.
- Developed a web-based calculator for individualized prognosis to aid clinicians and patients in decision-making.